Market News & Trends
8/23/2011
Intellipharmaceutics & Par Pharmaceutical Expand Development & Commercialization Agreement Intellipharmaceutics International Inc. recently announced that they have added the development and commercialization of additional strengths…
Alexza Pharmaceuticals Announces PDUFA Goal Date
Alexza Pharmaceuticals, Inc. recently announced the US FDA has accepted the ADASUVE NDA as a complete, class 2 response to the FDA's action letter, with…
DARA BioSciences Receives Fast-Track Designation for KRN5500
DARA BioSciences, Inc. recently announced its investigational drug KRN5500 has been granted Fast-Track designation by the US FDA for the treatment of chemotherapy-induced neuropathic pain…
Encap Drug Delivery Introduces Colon-Screen
Encap Drug Delivery recently announced it is now offering a feasibility package that will evaluate the potential to use candidate compounds in formulations suitable for…
8/16/2011
Boehringer Ingelheim Licenses ProBioGen's GlymaxX Technology Boehringer Ingelheim and ProBioGen AG recently announced they have signed a non-exclusive Licensing Agreement regarding ProBioGen's GlymaxX technology.…
Affymax Receives $10-Million Milestone Payment From Takeda
Affymax, Inc. recently announced it has received a $10-million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to…
Array BioPharma, Genentech Ink $713 Million Oncology Pact
Array BioPharma recently announced an oncology agreement with Genentech, a member of the Roche Group, for the development of each company's small-molecule Checkpoint kinase 1…
Boehringer Ingelheim Licenses ProBioGen's GlymaxX Technology
Boehringer Ingelheim and ProBioGen AG recently announced they have signed a non-exclusive Licensing Agreement regarding ProBioGen's GlymaxX technology. Boehringer Ingelheim's Contract Manufacturing Business will apply…
Bohai Pharmaceuticals Acquires Yantai Tianzheng Pharma for $35 Million
Bohai Pharmaceuticals Group, Inc. recently announced it has consummated a significant acquisition of a complementary Traditional Chinese Medicine (TCM) company in China, Yantai Tianzheng Pharmaceutical…
FDA Tentatively Approves Intelliject's Lead Product e-cue
Intelliject, Inc. recently announced the US FDA has granted tentative approval for the company's NDA for a novel epinephrine auto-injector, e-cue, for emergency treatment of…
Nycomed & Orion Corporation to Collaborate on Easyhaler
Nycomed recently announced it has entered into a collaboration agreement with Orion Corporation for the co-marketing of Easyhaler combination products for the treatment of asthma…
Trius & Bayer Form Strategic Collaboration
Trius Therapeutics, Inc. and Bayer Pharma AG recently announced they have signed an exclusive agreement to develop and commercialize Trius' lead Phase III antibiotic, torezolid…
8/9/2011
Celgene & Acceleron Enter Agreement Worth Up to $242 Million Celgene Corporation and Acceleron Pharma, Inc. recently announced they have entered into a joint…
Amarin Successfully Completes All Remaining Clinical Studies for NDA
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, recently announced the successful completion of all remaining studies required for the…
Baxter Oncology Establishes Baxter Ventures; Will Commit $200 Million in Early Stage Companies
Baxter International Inc. recently announced it has established Baxter Ventures to invest up to $200 million in equity in promising early stage companies developing therapies…
Celgene & Acceleron Enter Agreement Worth Up to $242 Million
Celgene Corporation and Acceleron Pharma, Inc. recently announced they have entered into a joint development and commercialization agreement for ACE-536 for the treatment of anemia.…
Ironwood & Depomed Announce Collaboration, Research & License Agreement
Ironwood Pharmaceuticals, Inc. and Depomed, Inc. recently announced that Ironwood has licensed worldwide rights to utilize Depomed's Acuform gastric-retentive drug delivery technology for an Ironwood…
Sunshine Biopharma Looking to Mimic Roche's Billion-Dollar Cancer Drug
Last year, over 260,000 new cases of breast cancer (invasive and in situ combined) were diagnosed in women in the US. Over the course of…
Acorda Therapeutics Announces Initiation of Phase I Clinical Trial in Patients With Heart Failure
Acorda Therapeutics, Inc. recently announced the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating…
Apricus Biosciences Files Marketing Application for Vitaros
Apricus Biosciences, Inc. recently announced its filing of a marketing application for Vitaros as a treatment for patients with erectile dysfunction (ED) in Switzerland, with…
